NEW YORK, Oct. 4, 2013 /PRNewswire/ -- Bernstein Liebhard LLP today announced that a class action has been commenced in the United States District Court for the Southern District of New York on behalf of all those who purchased securities of BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company") between August 8, 2011 through September 20, 2013, inclusive (the "Class Period").
BioScrip is a pharmacy benefit management and specialty pharmaceutical organization that partners with managed care organizations and healthcare providers to control prescription drug costs. The Company provides pharmacy benefit products and services and mail order pharmacy services, and is the fulfillment center for online retailers offering prescription and OTC products.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company improperly distributed the product Exjade through its specialty pharmacy operations; (2) the Company was in violation of certain federal and state laws and regulations; and (3) as a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.
On September 23, 2013, the Company announced in a Form 8-K, that it received a civil investigative demand issued by the United States Attorney's Office for the Southern District of New York and a subpoena from the New York State Attorney General's Medicaid Fraud Control Unit, regarding the distribution of the Novartis Pharmaceuticals Corporation product Exjade by the Company's legacy specialty pharmacy division.
On this news, BioScrip securities declined $2.60 per share or 23% within two trading sessions, to close at $8.47 per share on September 24, 2013.
Plaintiffs seek to recover damages on behalf of all Class members who invested in BioScrip securities during the Class Period. If you invested in BioScrip securities as described above during the Class Period, and either lost money on the transaction or still hold the security, you may wish to join in this action to serve as lead plaintiff. In order to do so, you must meet certain requirements set forth in the applicable law and file appropriate papers no later than November 29, 2013.
A "lead plaintiff" is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as lead plaintiff. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Bernstein Liebhard LLP, or other counsel of your choice, to serve as your counsel in this action.
If you are interested in discussing your rights as a BioScrip shareholder and/or have information relating to the matter, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or email@example.com.
Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients. It has been named to The National Law Journal's "Plaintiffs' Hot List" in each of the last ten years.
You can obtain a copy of the complaint from the clerk of the court for the United States District Court for the Southern District of New York.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Bernstein Liebhard LLP
|Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Conn's, Inc. (2014/3/7)|
|Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Molycorp, Inc. (2013/8/20)|
|Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Inteliquent, Inc. ()|
|Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Biolase, Inc. (2013/8/28)|
|Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against NuVasive, Inc. ()|
|Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Bankrate, Inc. ()|
|Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Galena Biopharma, Inc. (2014/3/6)|
|Bernstein Liebhard LLP Announces That a Class Action Has Been Filed Against Barnes & Noble, Inc. (2014/1/24)|
|Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Atossa Genetics, Inc. ()|
|Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Achillion Pharmaceuticals, Inc. (2013/10/17)|
|Cementos Bio-Bio SA||View cementos Stock Quote|
|Hebei Veyong Bio-chemical Co Ltd||View 600803 Stock Quote|
|Bio-Rad Laboratories Inc||View bio Stock Quote|
|Bio-Rad Laboratories Inc||View bio Stock Quote|
|Niusule Bio-Pharmaceutical Corp||View nius Stock Quote|
|Kiwa Bio-Tech Products Group Corp||View kwbt Stock Quote|
|Bio Clean International Inc||View bcle Stock Quote|
|Redpoint Bio Corp||View rpbc Stock Quote|
|Bio Solutions Corporation||View bisu Stock Quote|
|Bio-AMD Inc||View biad Stock Quote|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.